Beijing
Meikang Geno-immune Biotechnology Co., Ltd. has been deeply engaged in the
field of immunotherapy for over two decades, building a collaborative,
multi-technology R&D system for tumor immunotherapy. The company focuses on
three core technology pipelines: CAR-T therapy, engineered immune effector
(EIE) cell therapy, and dendritic cell (DC) vaccines. By combining a diverse
portfolio of antigen targets, it precisely recognizes and targets a range of
tumor antigens to establish durable anti-tumor immune mechanisms.
The company has now entered an advanced stage of clinical exploration. Working alongside multiple medical institutions to evaluate safety and efficacy, it conducts clinical studies of combination immunotherapies for hematologic malignancies and solid tumors, committed to delivering durable and stable anti-tumor responses for patients.
Professor Lung-Ji Chang is a tenured professor at the University of Florida, a National Distinguished Expert recognized by the Central Talent Work Coordination Group, a Beijing Overseas High-Level Talent, an awardee of the Shenzhen Peacock Plan, and President of the Shenzhen Geno-immune Medical Institute. He served as the US lead for the cancer and AIDS research program of the International Atomic Energy Agency (IAEA), and has long been devoted to advancing translational research and development in gene and immune cell therapy.
His research spans lentiviral vector system development, clinical exploration of gene therapy, anti-tumor and anti-infective immune cell technologies, stem cell clinical applications, immune effector cells and immune regulatory factors, and cell and gene therapies.
Gene immunotherapy R&D
Focus on research of immune‑cell and gene therapy, and build R&D pipelines for innovative anti‑tumor therapeutics
NCI project registration
Full‑process clinical research registration services under international standards
Biotechnology Services
Integrated services for CGT technical consultation and collaborative R&D
TEL：010-82346080About Us
Company ProfileNCI Project
Blood CancerService
Immune technology portfolioCase Study
Blood Cancer Research
Wechat
